Utah Medical talks back
This article was originally published in The Gray Sheet
FDA's public statements "have diminished the company's business through innuendo," by suggesting the firm's alleged QSR non-compliance impacts device safety and effectiveness, Utah Medical charges Aug. 30 in response to an Aug. 9 injunction suit (1"The Gray Sheet" Aug. 16, 2004, p. 6). The manufacturer denies the allegations, which date to 2001. FDA's actions have led competitors to wrongly suggest to customers the firm may be shut down, Utah Medical says. The firm concedes its "total dollar value of orders has remained about normal" in August, but adds that its own 10% customer loyalty discount, instituted Aug. 20, "may have a significant effect on net sales." Utah Medical repurchased about $3.1 mil. of stock between Aug. 1 and Aug. 17...
You may also be interested in...
Utah Medical Products will challenge during pre-trial discovery whether FDA's inspectional observations of the Midvale, Utah facility can be construed as QSR violations
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.